No definition available.
Sequelae of inflammatory diseases of the central nervous system
G6_NEUROINFSEQ
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
113 |
4. Check minimum number of eventsNone |
113 |
5. Include endpointsNone |
113 |
6. Filter based on genotype QC (FinnGen only) |
109 |
Control definitions (FinnGen only)
- Control exclude
- G6_NEUINFL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G00-G09
- Name in latin
- Sequelae morborum inflammatoriorum systematis nervosi centralis
Similar endpoints
↥List of similar endpoints to
Sequelae of inflammatory diseases of the central nervous system
based on the number of shared cases.
Similar with more cases:
- Inflammatory diseases of the central nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1421 | 653 | 746 |
| Only index persons | 880 | 437 | 443 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 43.55 | 45.47 | 41.45 |
| Only index persons | 36.06 | 39.65 | 32.52 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 109 | 53 | 56 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 39.29 | 32.32 | 45.88 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 113
- Matched controls
- 1130
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G09
ICD-10 Finland
Sequelae of inflammatory diseases of central nervous system
+∞
77.1
65
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
11.5
23.1
27
30
32400
ICD-8 Finland
Late effects of intracranial abscess or pyogenic infection, Hydrocephalus acquisitus
+∞
21.5
20
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.5
12.4
23
43
A86
ICD-10 Finland
Unspecified viral encephalitis
60.3
9.8
11
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.4
9.5
21
46
G06.0
ICD-10 Finland
Intracranial abscess and granuloma
+∞
9.5
9
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
14.2
9.2
15
12
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
8.4
8
*
XA800
NOMESCO Finland
Neuropsychological investigation
7.6
8.3
19
29
R51.80
ICD-10 Finland
Headache
3.5
7.8
34
124
G40.9
ICD-10 Finland
Epilepsy, unspecified
9.4
7.6
15
18
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
12.1
7.5
13
12
R42
ICD-10 Finland
Dizziness and giddiness
3.3
7.5
37
146
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.5
7.5
17
26
32401
ICD-8 Finland
Late effects of intracranial abscess or pyogenic infection, Status postencephaliticus
+∞
7.4
7
*
N03AF01
ATC
carbamazepine; oral, rectal
6.3
7.3
19
35
N03AF02
ATC
oxcarbazepine; oral
9.8
7.3
14
16
TAB00
NOMESCO Finland
Lumbar puncture
6.7
7.3
18
31
N03AE01
ATC
clonazepam; systemic
8.5
7.2
15
20
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
12.0
7.0
12
11
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.4
6.6
28
100
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.6
6.4
24
79
AA1AD
NOMESCO Finland
CT of head and brain
2.9
6.3
41
187
G04.8
ICD-10 Finland
Other encephalitis, myelitis and encephalomyelitis
+∞
6.3
6
*
N03AX18
ATC
lacosamide; systemic
+∞
6.3
6
*
2133
FHL
Suntin revisio
+∞
6.3
6
*
32408
ICD-8 Finland
Late effects of intracranial abscess or pyogenic infection, Alia definitae
+∞
6.3
6
*
SPAT1234
SPAT
Support of social functional capacity
6.5
6.1
15
26
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.3
6.1
26
93
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.2
6.1
28
105
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
9
8
12.08
5.39
1.2
1.0
—
—
—
0
0
8
7
12.17
4.86
1.3
1.0
—
—
—
0
0
8
9
9.45
4.35
1.3
1.0
—
—
—
0
0
11
23
5.18
3.99
3.5
1.0
454.73
2.88
e6/l
0.48
11
16
11
23
5.18
3.99
3.9
1.1
110.45
123.38
e6/l
0.04
11
16
6
5
12.56
3.80
1.3
1.0
—
—
—
0
0
30
151
2.34
3.58
1.6
1.7
1376.60
1201.12
nmol/l
0.58
25
115
20
88
2.55
3.16
3.4
7.9
1.16
1.07
mmol/l
0.05
13
75
10
28
3.81
2.86
1.4
1.0
—
—
—
0
0
5
6
8.64
2.77
1.4
1.0
—
—
—
0
0
5
6
8.64
2.77
1.0
1.2
—
—
—
0
0
6
10
6.26
2.73
1.2
1.1
—
—
—
0
0
5
7
7.40
2.57
1.0
1.0
—
—
—
0
0
28
158
2.03
2.47
2.3
2.7
2.45
2.48
mmol/l
0.55
22
137
6
13
4.81
2.30
3.0
2.7
106.33
107.77
mmol/l
—
6
13
8
24
3.51
2.22
1.5
1.3
—
—
—
0
0
56
408
1.74
2.18
15.2
11.8
1.15
1.27
inr
0.53
13
126
14
64
2.36
2.04
1.6
1.3
—
—
—
0
0
10
39
2.71
2.00
4.7
3.5
26.18
24.58
mmol/l
—
10
39
68
532
1.70
1.98
13.9
9.8
4.65
4.28
e9/l
0.50
63
475
17
86
2.15
1.97
2.8
1.6
276.18
385.34
nmol/l
2.58
17
77
6
16
3.90
1.96
1.5
1.2
—
—
—
0
0
9
34
2.79
1.91
2.2
2.5
—
—
—
0
0
18
95
2.06
1.88
8.2
6.8
—
—
—
0
0
9
35
2.70
1.84
7.3
3.0
37.81
51.76
%
—
9
35
5
13
3.97
1.73
1.6
1.5
—
—
—
0
0
56
427
1.62
1.72
8.9
6.9
1.21
1.22
mmol/l
0.73
50
370
23
138
1.84
1.68
1.7
1.9
—
—
—
0
0
37
256
1.66
1.66
3.0
3.0
775.41
1027.80
ng/l
0.22
32
214
8
33
2.53
1.57
1.9
2.8
—
—
—
0
0
6
21
2.96
1.52
1.2
1.2
—
—
—
0
0
6
21
2.96
1.52
1.0
1.1
—
—
—
0
0
9
38
2.48
1.49
1.4
2.3
—
—
—
0
0
5
17
3.03
1.37
2.4
1.2
—
—
—
0
0
14
76
1.96
1.37
2.9
2.5
0.20
0.23
g/l
0.49
14
71
55
435
1.52
1.35
7.6
4.8
0.00
0.00
estimate
-0.00
11
84
9
43
2.19
1.34
1.6
1.8
—
—
—
0
0
55
436
1.51
1.33
5.1
3.5
0.00
0.00
estimate
-0.00
11
91
21
132
1.73
1.32
2.5
2.6
1.75
3.01
e6/l
0.46
13
64
8
34
2.45
1.32
3.5
2.5
3.86
1.19
%
—
8
34
5
18
2.86
1.30
1.0
1.7
—
—
—
0
0
5
18
2.86
1.30
1.0
1.7
—
—
—
0
0
45
346
1.50
1.24
3.8
3.5
28.68
49.41
ng/l
0.66
38
232
14
79
1.88
1.23
3.6
2.6
10.81
13.88
nmol/l
1.10
14
74
5
19
2.70
1.23
8.6
1.8
—
—
—
0
0
8
38
2.19
1.21
1.8
1.8
39.63
34.55
nmol/l
—
8
38
84
926
0.64
1.19
4.7
4.8
2.79
2.78
mmol/l
0.03
79
868
15
91
1.75
1.07
1.5
1.8
—
—
—
0
0
54
441
1.43
1.06
5.0
3.5
0.00
0.00
estimate
—
9
82
40
309
1.46
1.06
3.8
2.9
—
—
—
0
0
43
337
1.45
1.05
5.3
3.6
—
—
—
0
0
7
34
2.13
1.05
1.7
2.1
—
—
—
0
0
15
92
1.73
1.03
1.4
1.7
—
—
—
0
0
79
874
0.68
1.02
4.0
3.9
1.41
1.31
mmol/l
0.49
73
816
0
29
0.00
0.99
0.0
1.4
—
223.09
—
0
17
21
145
1.55
0.93
2.5
2.4
0.91
1.02
e6/l
0.08
13
77
30
226
1.45
0.89
3.4
3.8
0.00
0.00
estimate
—
9
81
39
313
1.38
0.81
3.4
2.8
30.10
31.08
u/l
0.10
39
296
0
24
0.00
0.80
0.0
1.3
—
—
—
0
0
5
24
2.13
0.75
1.2
1.3
—
—
—
0
0
11
68
1.68
0.75
4.0
3.6
63.38
67.64
g/l
1.11
11
63
5
25
2.04
0.73
1.8
4.8
0.00
0.00
g/l
—
5
25
7
40
1.80
0.73
1.6
1.7
—
—
—
0
0
48
404
1.33
0.72
3.7
2.4
—
—
—
0
0
5
29
1.76
0.64
1.4
1.3
—
15.80
—
0
6
19
140
1.43
0.63
2.7
2.3
10.60
14.06
umol/l
0.62
19
129
8
52
1.58
0.61
1.4
1.3
—
—
—
0
0
37
311
1.28
0.54
2.7
3.4
2.35
2.35
mmol/l
0.07
32
274
23
182
1.33
0.52
5.2
2.9
21.06
111.87
ng/l
1.20
18
137
79
845
0.78
0.51
6.6
5.4
39.93
39.40
mmol/mol
0.22
74
799
17
131
1.35
0.45
1.4
1.8
1.43
1.49
%
0.08
17
113
5
31
1.64
0.43
1.6
1.4
—
—
—
0
0
5
33
1.54
0.42
1.8
4.0
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
2.30
—
0
15
5
34
1.49
0.41
8.2
1.9
—
—
—
0
0
38
336
1.20
0.35
2.0
2.0
93.62
99.25
pmol/l
0.32
19
167
29
250
1.22
0.34
4.3
2.8
0.14
0.30
e6/l
0.90
23
178
24
203
1.23
0.33
3.3
2.2
—
—
—
0
0
16
129
1.28
0.32
2.8
2.3
2.34
2.41
g/l
0.21
16
113
13
103
1.30
0.29
11.9
5.6
0.93
1.00
mmol/l
0.51
13
96
21
179
1.21
0.27
1.4
1.3
13.64
32.76
iu/ml
—
7
61
95
920
1.20
0.24
26.3
13.5
20.05
22.27
mg/l
0.35
84
730
0
11
0.00
0.21
0.0
1.2
—
4.62
—
0
5
0
10
0.00
0.21
0.0
1.5
—
218.30
—
0
10
0
10
0.00
0.21
0.0
1.3
—
203.07
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.8
—
89.23
—
0
13
10
120
0.82
0.17
2.2
2.0
—
—
—
0
0
20
223
0.87
0.16
3.4
4.0
16.97
22.88
%
—
7
92
15
171
0.86
0.16
2.2
1.5
—
—
—
0
0
59
616
0.91
0.15
2.8
3.1
—
—
—
0
0
9
108
0.82
0.13
1.9
1.9
—
—
—
0
0
12
137
0.86
0.12
2.0
1.4
—
—
—
0
0
14
157
0.88
0.12
2.5
2.7
0.39
0.75
ug/l
—
9
92
23
248
0.91
0.10
4.2
3.7
7.16
10.65
mg/mmol
0.21
15
155
5
43
1.17
0.10
5.8
6.2
24.74
24.80
mmol/l
—
5
43
5
45
1.12
0.10
1.0
1.5
—
—
—
0
0
6
55
1.10
0.09
6.3
2.8
2.38
1.15
mmol/l
—
6
41
101
1023
0.88
0.09
34.2
19.8
39.25
40.74
%
1.02
95
970
7
67
1.05
0.08
3.7
1.8
465.71
118.09
ng/l
—
7
58
8
75
1.07
0.07
5.1
3.3
—
—
—
0
0
88
867
1.07
0.06
18.0
12.9
84.59
83.21
ml/min/173m2
0.21
80
715
28
292
0.95
0.05
4.3
4.2
1.16
1.98
ug/l
1.31
28
268
80
792
1.03
0.02
26.5
16.5
15.19
15.09
%
0.06
80
781
97
973
0.98
0.00
25.3
15.5
75.66
77.12
umol/l
0.15
97
973
84
839
1.00
0.00
5.5
4.7
1.82
1.84
mu/l
0.06
78
775
16
164
0.97
0.00
1.4
1.3
1.14
8.62
u/ml
—
7
60
21
211
0.99
0.00
1.5
1.2
3.05
1.05
u/ml
—
6
60
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
8.43
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
13.00
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_NEUROINFSEQ and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_NEUROINFSEQ | 2.449 [1.58, 3.79] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.263 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 211 females with G6_NEUROINFSEQ died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have G6_NEUROINFSEQ.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.273% | No data |
| 5 | 1.534% | No data |
| 10 | 3.802% | No data |
| 15 | 6.743% | No data |
| 20 | 11.591% | No data |
Relationships between endpoints
↥Index endpoint: G6_NEUROINFSEQ – Sequelae of inflammatory diseases of the central nervous system
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data